Price Chart

Profile

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
URL https://www.aclaristx.com
Investor Relations URL https://www.aclaristx.com/#!investors/juser
HQ State/Province Pennsylvania
Sector Healthcare
Industry Diagnostics & Research
Equity Style Small Cap/Blend
Next Earnings Release Feb. 23, 2024 (est.)
Last Earnings Release Nov. 06, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
URL https://www.aclaristx.com
Investor Relations URL https://www.aclaristx.com/#!investors/juser
HQ State/Province Pennsylvania
Sector Healthcare
Industry Diagnostics & Research
Equity Style Small Cap/Blend
Next Earnings Release Feb. 23, 2024 (est.)
Last Earnings Release Nov. 06, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A